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Abstract.  We have compared the molecular specifici- 
ties of the adhesive interactions  of melanoma and 
fibroblastic cells with fibronectin.  Several striking 
differences were found in the sensitivity of the two cell 
types to inhibition by a  series of synthetic peptides 
modeled on the Arg-Gly-Asp-Ser (RGDS) tetrapeptide 
adhesion signal.  Further evidence for differences be- 
tween the melanoma and fibroblastic cell adhesion sys- 
tems was obtained by examining  adhesion to proteo- 
lytic fragments of fibronectin.  Fibroblastic BHK cells 
spread readily on f13, a 75-kD fragment representing 
the RGDS-containing,  "cell-binding" domain of 
fibronectin, but B16-F10 melanoma cells could not. 
The melanoma cells were able to spread instead on f9, 
a  ll3-kD fragment derived from the large subunit of 
fibronectin that contains at least part of the type III 
connecting segment difference region (or "V" region); 
f7, a fragment from the small fibronectin subunit that 
lacks this alternatively spliced polypeptide was inac- 
tive.  Monoclonal antibody and f13 inhibition  experi- 
ments confirmed the inability of the melanoma cells to 
use the RGDS sequence; neither molecule affected 
melanoma cell spreading,  but both completely 
abrogated fibroblast adhesion.  By systematic analysis 
of a  series of six overlapping synthetic peptides span- 
ning the entire type III connecting segment, a novel 
attachment site was identified in a peptide near the 
COOH-terminus of this region.  The tetrapeptide se- 
quence Arg-Glu-Asp-Val  (REDV), which is somewhat 
related to RGDS, was present in this peptide in a 
highly hydrophilic region of the type III connecting 
segment.  REDV appeared to be functionally impor- 
tant,  since this synthetic tetrapeptide was inhibitory for 
melanoma cell adhesion to fibronectin but was inactive 
for fibroblastic cell adhesion.  REDV therefore 
represents a novel adhesive recognition signal in 
fibronectin that possesses cell type specificity. These 
results suggest that,  for some cell types, regulation of 
the adhesion-promoting activity of fibronectin may oc- 
cur by alternative mRNA splicing. 
C 
ELLULAR adhesion  to extracellular  matrices occurs 
during  many important  biological  events, including 
growth, development,  and disease pathogenesis (1, 4, 
14, 18, 22, 26, 37, 45, 56, 58). A better understanding  of the 
biochemical  interactions  involved  in  cell  adhesion  would 
yield valuable insights into the regulation of these processes. 
Considerable progress has been made recently by studying 
the molecular basis of the interaction of ceils with the proto- 
type adhesion  factor fibronectin  (for reviews see 4, 22, 25, 
26, 46, 61). 
Intact fibronectin  binds with moderate affinity (Kd =  8 × 
10  -7 M)  to  a  relatively  abundant  fibroblastic  cell  surface 
receptor population  (2). This direct binding interaction is in- 
hibited  in a competitive manner both by well-characterized 
cell-binding  fragments  of fibronectin  (5),  and by synthetic 
peptides derived from the primary sequence of the fibronec- 
tin molecule (3).  The sequence of the minimal  cell recog- 
nition  site in  the "cell-binding"  domain of fibronectin  has 
been recently identified as the tetrapeptide  Arg-Gly-Asp-Ser 
(RGDS) (40-42, 63, 64). Synthetic peptides containing  this 
sequence mediate cellular attachment  when immobilized  on 
a suitable substrate (40-42), and are autoinhibitory  in assays 
monitoring  the adhesion  of fibroblastic  cells to both intact 
fibronectin  (40, 41,  63,  64)  and  its purified  "cell-binding" 
domain (63). 
The RGDS sequence in fibronectin  is present in a highly 
hydrophilic region at a predicted ~-turn (40), which suggests 
that  it is located at an exposed surface site accessible for 
binding  to the fibronectin  receptor.  RGDS-containing  pep- 
tides  have  recently  been  used  in  nonimmunological  ap- 
proaches for identification  of the fibronectin receptor (6, 21, 
44), and for investigating the role of this adhesive  recogni- 
tion  signal in relevant biological  processes in vivo such as 
experimental  metastasis  (24),  embryonic development  (9), 
and platelet function  (13, 17). 
Although evidence is strongest for the interaction  of cells 
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some indications of possible additional cell-binding regions 
or mechanisms within fibronectin. (a) The affinity of syn- 
thetic peptides, or even of an ll.5-kD cell-binding fragment, 
for fibroblasts is substantially lower than larger fragments or 
the intact molecule (3, 5), suggesting that sequences outside 
of RGDS are required for full biological activity of fibronec- 
tin. (b) Sialylated gangliosides have been reported to inter- 
fere with fibronectin-mediated adhesion in vitro (27, 67). 
Studies with a ganglioside-deficient mutant cell line, which 
is unable to retain endogenously synthesized fibronectin on 
its cell surface, have shown retention and reorganization of 
the pericellular fibronectin matrix after exogenous ganglio- 
side addition (50,  51, 66).  Recently, a ganglioside-binding 
domain that may be responsible for this effect has been iden- 
tified in fibronectin (55). Binding activity resides in a region 
of fibronectin distinct from the "cell-binding" domain. (c) 
Comparisons of  the adhesion-promoting activity of fibronec- 
tin, fibronectin fragments, and the heparan sulfate-binding 
protein, platelet factor 4, have suggested that heparan sulfate 
proteoglycan may mediate some aspects of  the adhesion pro- 
cess, perhaps in concert with the "cell-binding" domain of 
fibronectin (8, 31, 60). Furthermore, attachment-promoting 
activity for mouse melanoma cells has been identified in a 
proteolytic fragment of fibronectin containing the COOH- 
terminal heparin-binding site (32). (d) Kinetic analysis of  the 
incorporation of exogenous fibronectin into cell layers has 
suggested that assembly of the fibronectin matrix may be 
mediated by the NH2-terminal 70-kD domain (33). 
In this study, we have compared the specificities of the 
adhesive interactions of B16-F10 murine melanoma cells and 
fibroblastic baby hamster kidney (BHK) cells with fibronec- 
tin,  using a  library of synthetic peptides modeled on the 
RGDS sequence. Differences were detected in the profile of 
inhibition of adhesion by the peptide homologues, which can 
be ascribed to the use of different adhesive recognition sig- 
nals by the two cell lines. BHK cells use the well-character- 
ized RGDS sequence, whereas B16-F10 ceils recognize a sec- 
ond site involving the type III connecting segment region of 
the fibronectin molecule that appears to be distinct from any 
of the other proposed cell interaction sites discussed above. 
Materials and Methods 
Materials 
Fibronectin was purified from freshly frozen, citrated human plasma (Na- 
tional Institutes of Health Blood Bank, Bethesda, MD) by gelatin affinity 
chromatography using elution with citric acid as described (35, 62). Tryptic 
fragments of fibronectin (t7, t9, and f13) were isolated as described (19). 
Labeling of fibronectin and f13 with carrier-free [3H]sodium borohydride 
(New England Nuclear, Boston, MA) was carried out as described (2, 52). 
29-kD and 38-kD fragments of fibronectin containing the COOH-terminal, 
high affinity heparin-binding sites from the large and small subunits, respec- 
tively, were isolated by thermolysin digestion, chromatography on hydrox- 
ylapatite, and gel filtration (68). Custom synthesis of tetra- and pentapep- 
tides  was  carried  out  by  Peninsula  Laboratories,  Inc.  (Belmont,  CA). 
Peptides were further purified as described (24). Synthesis of longer pep- 
tides is described below. The isolation and characterization of monoclonal 
antibody 333 (mAb333) has been described previously (5). Thr-Lys-Pro- 
Arg (TKPR; tuflsin), and Gly-His-Lys (GHK; liver cell growth factor) were 
from Bachem Inc. (Torrance, CA). Insulin A chain, fibrinopeptide A, Arg- 
Asp (RD),  and  Arg-Gly-Pro-Phe-Pro-lle  (RGPFPI;  sexual  agglutination 
peptide) were from Sigma Chemical Co.  (St.  Louis,  MO). 
Cell-spreading  Assay 
B16-FI0 murine melanoma cells (10) (generously provided by Dr. I. J. Fid- 
let,  M.  D.  Anderson Hospital,  University of Texas,  Houston,  TX)  and 
fibroblastic BHK cells were cultured as described (U, 23, 63).  Spreading 
assays on fibronectin or  its proteolytic  fragments were performed  by  a 
modification of the method of Yamada and Kennedy (63). Adhesion factors 
were diluted  into Dulbecco's  phosphate-buffered saline (PBS+) I  (Gibco, 
Grand Island, NY), and 100-~tl aliquots were added to 6.4-mm (96-well) tis- 
sue culture clusters (Costar,  Cambridge,  MA).  After incubation at room 
temperature for 60 rain, sites for nonspecific cell attachment to the plastic 
surface were blocked by incubation with 100 ~tl 10 nag/nil heat-denatured 
BSA. This blocking solution was prepared by dissolving crystalline BSA 
(Caibiochem-Behring Corp.,  La Jolla, CA) in divalent cation-free PBS  + 
(PBS-), filtering the mixture, and heating in a water bath at 85"C for 10 
rain. After a 30-rain incubation at room temperature, the BSA solution was 
removed and 25-1~1 peptide solutions in PBS  + were added. 
Cell  cultures were  washed with  PBS-,  and ceils were detached  with 
0.25% trypsin, 0.02% EDTA, then washed and resuspended to 1.3  x  105 
cells/ml in DME. Cell suspensions were allowed to recover from the proteo- 
lyric treatment for 10 min at 3"/*C before addition of 75-1~1 aliquots to the 
96-well clusters. After incubation for 60 rain at 370C,  attached cells were 
fixed with 3 %  formaldehyde and  3%  glutaraldehyde  in PBS-  and pho- 
tographed using phase-contrast microscopy. The percentage of cells adopt- 
ing  a  normal,  well-spread  morphology  was  estimated  by  counting  300 
cells/well in a number of randomly selected fields. 
The assay measuring cell spreading on immobilized peptides was carried 
out as described above except that 96-well clusters (Linbro Titertek; Flow 
Laboratories,  Inc.,  McLean,  VA) were coated with peptide for 2  h  and 
nonspecific adhesion was reduced by blockage with 10 ~tg/ml BSA in PBS  + 
forl  h. 
Synthesis of CS Peptides 
Overlapping peptides comprising the type III connecting segment (IIICS) 
of human plasma fibronectin were synthesized according to the method of 
Merrifield (34) using an Applied Biosystems 430A peptide synthesizer. The 
symmetric anhydrides of t-butyloxycarbonyl-protected amino acids  (59) 
were used for dicyclohexylcarbodiimide-mediated coupling to the peptide 
chain. The recently developed phenylacetamidomethyl-resin (36) was used 
as a solid support. Peptides were cleaved from the support by treatment with 
anhydrous hydrogen fluoride for 1 h at 0°C in the presence of 10% (vol/vol) 
anisole and 1% (vol/vol) dimethylsulfide. After extraction with 50% (vol/ 
vol) acetic acid, the peptides were chromatographed on Bio-Gel P4 using 
1 M acetic acid as eluant. Fractions containing peptide were lyophilized and 
further purified as described below. 
Purity of  Polypeptide Fragments and 
Synthetic Peptides 
The purity of tryptic fragments of fibronectin (17, 19, and f13) was assessed 
by serial dilution and SDS PAGE (using 4 % stacking and 8 % resolving gels) 
followed by Coomassie Blue staining. Fragments were 90-98% pure by this 
method; 19 was >/95% pure. 
Synthetic peptides purified by Bio-Gel P4 chromatography were further 
purified to homogeneity by semi-preparative, reversed-phase HPLC. A Syn- 
chropak RP-P C18 column (250 mm x  10 nun; SynChrom, Inc., Linden, 
IN)  was equilibrated with 0.1%  trifluoroacetic acid at a  flow rate of 1.0 
ml/min and, after injection of peptide in the same solvent, the column was 
developed by a linear gradient of 0-10% acetonitrile in 0.1% trifluoroacetic 
acid over a 3-min period followed by a further linear gradient of 10-50% 
acetonitrile in 0.1% trifluoroacetic acid over a 30-rain period. By monitoring 
absorbance at 220 ran, peptides were found to elute as single major peaks. 
The main peaks were pooled, lyophilized, and rechromatographed on a Syn- 
chropak RP-P C18 analytical column (250 mm x  4.1 mm; SynChrom, Inc.) 
using the gradient conditions described above and a flow rate of 0.8 mi/min. 
Peptides eluted between 21 and 34% acetonitrile and were 95.1-99.4% pure 
(CS5 was 98.5% pure) after peak integration. CS peptides were labeled by 
reductive  methylation  of  free  primary  amino  groups  with  [3H]sodium 
borohydride (New England Nuclear) as described (52). 
1.  Abbreviations  used in this paper:  IIICS,  type III connecting segment; 
PBS  +,  Dulbecco's  phosphate-buffered  saline;  PBS-,  divalent cation-free 
PBS  +. 
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Figure 1.  Comparison of the 
inhibitory effects of a series of 
tetra- and pentapeptides mod- 
eled  on the  RGDS  sequence 
on cell spreading on fibronec- 
tin.  The  percentage  of  (A) 
BHK fibroblasts or (B) B16- 
F10 melanoma cells adopting 
a spread morphology on sub- 
strates  coated  with  2  txg/ml 
(A)  or  4  ~tg/ml (B)  human 
plasma fibronectin is shown at 
the  indicated  concentrations 
of synthetic peptide. 
Results 
Comparison of the Effects of  Synthetic Peptides 
on Melanoma and Fibroblastic Cell Adhesion 
to Fibronectin 
Recently,  libraries  of short,  synthetic  peptides  have been 
used to examine the specificity of cellular interactions with 
fibronectin and other extracellular matrix components (13, 
17, 40,  41, 43,  49,  63,  64).  In general,  peptides containing 
the RGDS sequence have been found to be the most effective 
inhibitors of adhesive function, whereas other homologues 
in which amino acids are deleted, substituted, or transposed 
are much less active. The relative activities of RGDS homo- 
logues can therefore be used to assess the specificity of a cell- 
adhesion protein interaction. 
The data presented in Fig. 1 show a comparison of the rela- 
tive inhibitory activity of a series of homologous peptides on 
the  fibronectin-mediated  spreading  of B16-F10 melanoma 
and BHK fibroblastic cells. A number of unexpected differ- 
ences were found in the ability of the peptides to interfere 
with the adhesion of these two cell lines.  Consistent with 
previous reports using a variety of fibroblastic cell lines (40, 
41, 49, 63, 64), fibronectin-mediated spreading of BHK cells 
was inhibited by (G)RGDS, a peptide that occurs in the pri- 
mary sequence of the "cell-binding" domain of fibronectin, 
and SDGR, a peptide with an inverted sequence (Fig.  1 A). 
For BHK cells, GRGDS was consistently more active on a 
molar basis than both RGDS and SDGR. The specificity of 
the inhibition of BHK cell spreading was apparent from the 
complete lack of inhibitory activity in three peptides con- 
taining either a  deletion of the COOH-terminal residue of 
GRGDS (GRGD), a conservative substitution of a glutamic 
acid  residue  for an  aspartic  acid  residue  (GRGES),  or a 
transposition of the central glycine and aspartic acid residues 
(GRDGS) (Fig.  1 A). 
Parallel examination of the effects of each of these six pep- 
tides on B16-F10 melanoma cell spreading revealed several 
striking differences compared with BHK cells (Fig. 1 B). Al- 
though GRGDS, RGDS, and SDGR were again inhibitory, 
the  relative activities of each were considerably different. 
RGDS was the most active, followed by SDGR and GRGDS 
(Fig.  1 B). As for BHK cells, GRDGS was inactive, but for 
the melanoma cells both GRGD and GRGES were found to 
possess substantial activity. In particular, the concentrations 
of GRGDS and GRGES required for half-maximal inhibition 
were quite similar (230  I.tg/ml and 310 gg/ml respectively; 
Fig. 1 B). The marked inhibition by GRGES in Fig. 1 B con- 
trasts markedly with previous results with fibroblastic cells 
(40,  41,  63,  64). 
The inhibition by peptides in Fig. 1 was competitive in na- 
ture, since increasing the level of substrate-adsorbed fibro- 
nectin to 50 Ixg/ml was in all cases sufficient to overcome the 
inhibitory activity of each peptide (data not shown). This re- 
sult  also establishes that  the data  cannot  be explained by 
selective cytotoxicity of the synthetic peptides for the mela- 
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Figure 2. Map of the human plasma fibronectin dimer to show the 
derivation of  the fragments used in this study. The sites of the RGDS 
tetrapeptide  and the IIICS region are highlighted  in the hatched 
areas. The binding specificities of the different fibronectin domains 
are listed under the diagram.  The amino and carboxyl termini of 
the fibronectin chains are indicated by N and C, respectively. 
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tivity to peptide inhibition of a  mouse fibroblast cell line 
(BALB/c-3T3) with  the  mouse melanoma ceils  (B16-F10) 
gave the same pattern of results as for BHK fibroblasts (data 
not shown);  even primary cell strains of chick fibroblasts 
showed identical patterns of sensitivities (65), ruling out an 
artefact of the fibroblast species used.  Similarly, culturing 
BHK fibroblasts for 1 wk in the same growth medium used 
for melanoma ceils did not affect their pattern of inhibition 
by the peptide library (data not shown), indicating that the 
difference in susceptibility to peptide inhibition was not at- 
tributable to the growth medium used for routine culture. 
Furthermore, the data in Fig. 1 did not arise from a complete 
breakdown in the specificity of peptide-mediated inhibition 
of the melanoma cells, since a number of synthetic peptide 
molecules unrelated to RGDS were completely inactive at 
concentrations up to 1 mg/ml (including TKPR, GHK, insu- 
lin A chain, fibrinopeptide A, RD,  and RGPFPI [data not 
shown]; GRDGS was also inactive [Fig. 1 B]). These results 
in particular suggest that an RGD-type mechanism may be 
involved in B16-F10 melanoma cell spreading, but the differ- 
ent pattern of inhibition by RGDS homologues nevertheless 
reflects a novel profile of specificity for a cellular interaction 
with fibronectin. 
Promotion of  Melanoma and Fibroblastic Cell 
Spreading by Proteolytic  Fragments  of  Fibronectin 
Two possible explanations for the differences in the profile 
of  peptide inhibition in Fig. 1 were as follows: (a) the two cell 
types were recognizing different sites in fibronectin, or (b) 
the binding site of the fibronectin receptor of melanoma cells 
was altered, resulting in a less specific recognition of RGDS- 
like sequences compared with BHK cells. To investigate the 
first possibility, we compared the spreading of BI6-FI0 and 
BHK cells on different purified tryptic fragments of fibronec- 
tin. The fragments tested have been previously characterized 
in detail, and are designated f7, 19, and f13 (19). Fig. 2 is a 
map of the human plasma fibronectin dimer showing the ori- 
gin of these fragments, f13 is a 75-kD polypeptide constitut- 
ing the trypsin-resistant "cell-binding" domain, while f7 and 
19 contain COOH-terminal extensions of f13 derived from 
the small and large subunits of the fibronectin dimer, respec- 
tively, t9 (113 kD) incorporates f13 together with the adjacent 
heparin-binding domain and at least part of the type III con- 
necting segment (IIICS) or "V" region. IIICS is the region 
alternatively spliced in fibronectin mRNA that is thought to 
determine  the  size  difference between  each  chain  of the 
plasma fibronectin dimer; it appears to be located predomi- 
nantly in the large subunlt (25,  39, 47).  t7 (146 kD) is the 
corresponding fragment derived from the small subunit. In 
addition  to  the  heparin-binding  domain,  17  contains  the 
COOH-terminal fibrin-binding domain and therefore spans 
the site where IIICS is spliced out of the molecule (19). 
As previously reported (19), the concentration dependence 
of BHK fibroblast cell spreading was similar on fibronectin 
and the three tryptic fragments when the coating concentra- 
tion of polypeptide was expressed on a molar basis (Figs. 3 
A  and  4).  The concentration required  for 50%  maximal 
spreading typically varied between 4  nM and 7  nM.  The 
spreading of B16-F10 melanoma cells on intact fibronectin 
was comparable to BHK, with 50% maximal spreading ob- 
served at 7 nM and 4 nM, respectively (Fig. 3). However, 
the melanoma cells were strikingly poorly adhesive on a sub- 
strate of f13, with only 10% spreading occurring at even 53 
nM (Figs. 3 B and 4). Examination of the effects of higher 
coating concentrations of f13 revealed that 50 % of maximal 
spreading was only obtained at >--530 nM, a concentration at 
least 75-fold higher than that needed for equivalent spreading 
on fibronectin, and 100-fold higher than the concentration re- 
quired for 50 % maximal spreading of BHK on f13 (Fig. 3 A). 
This finding suggests that for spreading on fibronectin, the 
melanoma cells either use a site distinct from RGDS or at 
least  require  adjacent  contributory  site(s)  outside  of the 
75-kD "cell-binding" domain to be able to use the RGDS se- 
quence. Although the ability of BHK cells to respond to t"13 
is a direct, positive control for the absence of activity of the 
melanoma cells, we also measured the binding of radiola- 
beled fibronectin and f13 to plastic to discount the possibility 
that the poor spreading of B16-F10 cells on f13 was due to the 
inability of the protein to bind to the wells. 3H-labeled f13 
was  found  to  bind  ~l.2-fold  better  than  [3H]fibronectin 
when expressed on a molar basis (data not shown). 
When the spreading of melanoma ceils on the larger frag- 
ments 17 and 19 was examined, 19 was found to be as fully 
effective as intact fibronectin in supporting adhesion (50% 
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Figure 3. Analysis of the con- 
centration dependence of the 
spreading of (.4) BHK fibro- 
blasts or  (B)  B16-F10 mela- 
noma cells on fibronectin or 
its  tryptic  fragments,  f7,  t9, 
and f13. The coating concen- 
trations of all four molecules 
are expressed on a molar basis 
to permit comparison. 45 nM 
fibronectin monomer is equal 
to 12 t.tg/ml. 
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spreading of B16-FI0 melanoma cells (a-c) and 
BHK fibroblasts (d-f) on a control substrate (a 
and d) or on wells coated with 45 nM fibroneetin 
(12 Ixg/ml; b and e) or 53 nM f13 (4 ~tg/ml; c and 
f). Bar, 50 ~tm. 
of maximal  spreading  at 4  nM  and  7  nM,  respectively), 
whereas 17, like f13, was poorly adhesive (50 % of maximal 
spreading at 85 riM; i.e., >10-fold less active than 19; Fig. 
3 B). This result suggests that the particular amino acid se- 
quence influencing melanoma cell adhesion is located in the 
type lIl connecting segment of the large subunit, since this 
site is the only known region present in 19 but absent in 17. 
One possible explanation for the very slight activity of 17 in 
supporting melanoma cell spreading could be minor contam- 
ination with 19, co-purified from an ion exchange chroma- 
tography step of the isolation process (19).  Although both 
fragments were pure according to PAGE, a 5 % level of con- 
tamination of 17 with 19 could conceivably account for the 
results in Fig. 3 B. Alternatively, 17 activity could be due to 
the presence of a limited population of"small" subunits con- 
taining the active sequence. At present, the quantitative dis- 
tribution of different partial,  alternatively spliced products 
between the two human plasma fibronectin subunits is not 
known. 
Since both f7 and t9  contain the COOH-terminal,  high 
affinity heparin-binding domain (19), yet only 19 possesses 
spreading activity for B16-F10 melanoma cells, it is unlikely 
that  the  heparin-binding  site  mediates  the  adhesion  ob- 
served. Consistent with this interpretation, addition of hepa- 
rin up to a concentration of 1 mg/ml was found to have no 
detectable effect on melanoma cell spreading on fibronectin 
(data not shown). The independence of the adhesion site for 
B16-F10 melanoma cells from the heparin-binding domain 
was confirmed by examining spreading on 29-kD and 38-kD 
heparin-binding fragments isolated by thermolysin digestion 
of fibronectin and chromatography on hydroxylapatite (68; 
see also Fig. 2).  Despite retention of their heparin-binding 
activities,  neither  fragment possessed  any  activity  in  the 
spreading assay (data not shown). 
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I~gure 5.  Comparison of the inhibitory effects 
of (A)  an excess of cell-binding fragment f13 
and (B) anti-cell-binding monoclonal antibody 
mAb333 on spreading of BHK fibroblasts (open 
circles) and B16-F10  melanoma cells (closed cir- 
cles) on fibronectin. The percentage of cells ex- 
hibiting a normal spread morphology on a sub- 
strate coated with either 2  ltg/ml (BHK) or 4 
I~g/ml (B16-FI0)  fibronectin is shown at the indi- 
cated concentrations of inhibitor. The different 
fibronectin concentrations were chosen to yield 
approximately equivalent spreading of the two 
cell lines. Error bars  =  SD. 
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Figure 6. Scheme for synthesis of peptides spanning the IIICS region of human fibronectin. The six CS peptides were designed with a 
three-amino acid overlap so that every possible tetrapeptide was contained within at least one peptide. In addition, CSI was designed to 
contain residues 1-25 of the IIICS. This region comprises an entire spliced segment; the splice site between residues 25 and 26 is denoted 
by an asterisk. Similarly, the junction between CS4 and CS5 was designed around a second splice site between residues 89 and 90. The 
lengths of the six peptides are 25, 25,  24, 27, 20,  and  14 amino acids for CS1-CS6,  respectively. 
Effects off13 and a Monoclonal Antibody 
on Melanoma and l~broblastic Cell Spreading 
on Fibronectin 
To confirm the finding that B16-F10 melanoma cells do not 
use  the  RGDS  sequence  when  spreading  on  fibronectin, 
agents shown previously to be inhibitory for adhesion to the 
"cell-binding" domain were tested for their effects on B16-F10 
cell spreading on fibronectin. These molecules were (a) the 
f13  fragment itself,  and  (b)  a  monoclonal  antibody  desig- 
nated 333 (mAb333) that binds near the RGDS sequence in 
f13 and  that  inhibits  direct binding  of fibronectin  to BHK 
fibroblasts in suspension  (1). 
Consistent with earlier findings (63), fragment f13 was au- 
toinhibitory  for the  spreading  of BHK cells  on  substrate- 
adsorbed  fibronectin.  Essentially  complete  inhibition  of 
spreading was obtained with 1.5 mg/ml f13; half-maximal in- 
hibition occurred at 0.8 mg/ml (Fig. 5 A). Similarly, addition 
of mAb333  to  the  incubation  medium  of BHK ceils  was 
highly  inhibitory,  with  a  50%  decrease  in  spreading  ob- 
served at 3.5  ttg/ml (Fig.  5  B).  In contrast,  BI6-F10 mela- 
noma cells were highly resistant to the effects of both t"13 and 
mAb333.  No inhibition of spreading was observed, even at 
concentrations  10-fold in excess of the levels eliciting 50% 
inhibition of BHK adhesion (Fig.  5).  These results demon- 
strate that the RGDS-containing region in f13 is not used by 
B16-FI0 melanoma cells for spreading on intact fibronectin. 
Identification of  a Melanoma Cell Adhesion 
Site in Fibronectin 
Our  strategy  for identifying  a  specific  sequence  of amino 
acids capable of mediating B16-F10 melanoma spreading on 
fibronectin is outlined in Fig. 6. We conducted a  systematic 
analysis of overlapping synthetic peptides covering the entire 
IIICS region of human fibronectin.  A  total of six peptides 
were required to span the 120 amino acid residues. An over- 
lap of three amino acids was incorporated into each peptide 
to ensure that every possible tetrapeptide sequence was pres- 
ent in at least one molecule. 
A comparison of the ability of each of the connecting seg- 
ment (CS) peptides to mediate cell spreading after direct at- 
tachment to plastic is shown in Figs.  7  and  8.  None of the 
CS peptides were able to support BHK fibroblast cell spread- 
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Figure  7.  Concentration  de- 
pendence of the spreading of 
(A) BHK fibroblasts and (B) 
B16-F10  melanoma  cells  on 
substrate-adsorbed  CS  pep- 
tides.  Background  spreading 
was reduced by preincubation 
of wells with  10  I~g/ml BSA 
for 1 h at room temperature, 
and is indicated by the dashed 
line (zero in A.) The degree 
of spreading obtained with 4 
I~g/ml fibronectin is shown by 
the open circles.  The results 
are corrected for the amount 
of CS peptide bound to each 
well,  determined by measur- 
ing the degree of adsorption of 
radiolabeled peptide. After in- 
cubation at room temperature 
for 2 h, unbound peptide was 
washed away, and the bound 
peptide was removed by treatment with 1% SDS/1 N NaOH, and quantitated  by scintillation counting.  At a coating concentration of 0.1 
mg/ml, the amount of each peptide bound was 1.40, 0.71, 1.19, 0.71, 1.30, and 0.70% of the original amount added to each well for CS1-CS6, 
respectively.  Optimal spreading of BI6-FI0 melanoma cells on CS5 (",,5  x  10-" mol bound) was obtained at a coating concentration of 
0.1 mg/ml. 
The Journal of Cell Biology, Volume 103, 1986  2642 Figure 8. Phase-contrast microscopy of the spreading of B16-F10 melanoma cells (a-d) and BHK fibroblasts (e-h) on control substrates 
(a and e) or on wells coated with 4 gg/ml fibronectin (b and f), 0ol mg/ml CS4 (c and g), or 0.1 mg/ml CS5 (d and h).  Bar, 50 ~tm. 
ing (Figs. 7 A and 8). In contrast, plastic wells coated with 
CS5 (comprising residues 90-109 of the IIICS) promoted full 
spreading of B16-F10 melanoma cells (Figs. 7 B and 8). All 
of the other CS  peptides  were inactive for the melanoma 
cells, demonstrating that for this assay,  the adhesion site for 
these cells was limited to a sequence within this 20-amino 
acid peptide.  The results presented in Fig.  7 are corrected 
for the amount of adsorbed peptide, determined by measur- 
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Figure 9. Analysis of  the hydrophilicity of the IIICS region as calcu- 
lated by the methods of Hopp and Woods (20). Hydrophilicity was 
averaged over five residues. The bars indicate the site of the CS5 
peptide  and  the  REDV tetrapeptide.  The three most prominent 
hydrophilic segments are hatched. 
ing the binding of each 3H-labeled peptide to the wells. As 
described in the legend to Fig. 7, the CS1 peptide (inactive) 
bound best, followed by CS5 (active), CS3, CS2, CS4, and 
CS6 (all inactive). However, the largest differences in bind- 
ing were only twofold (CS1 vs. CS6). Therefore, the results 
in Fig. 7 cannot be explained by any differences in binding 
of the active CS5 peptide to the dish. Comparison of the mo- 
lar amounts of immobilized CS5 and fibronectin required to 
promote optimal spreading of B16-F10 melanoma ceils re- 
vealed that ~230-fold more CS5 was needed. This finding 
is similar to that observed for the RGDS sequence, where 
synthetic peptides were approximately two orders of magni- 
tude less active than fibronectin (3, 5, 40). It is possible that 
adjacent amino acid sequences are required either to provide 
additional binding activity or for correct conformation, or 
alternatively a short peptide fragment may lose activity after 
adsorption to plastic, as found even for intact fibronectin un- 
der certain circumstances (15). 
Localization of  Function in a Novel 
Tetrapeptide Sequence 
Fig. 9 shows an analysis of the IIICS region for hydrophilic- 
ity calculated by the methods of Hopp and Woods (20). It re- 
veals  three  particularly  hydrophilic polypeptide sites  that 
might be expected to  be well  exposed on the protein for 
potential  interactions  with  cells.  Analysis  by  the  use  of 
several other averaging parameters (averaging over 3, 7, 9, 
or 11 amino acids) as well as by the hydropathicity algorithm 
of Kyte and Doolittle (30) gave similar results.  The active 
CS5  region  was  found to  contain  one  of these  short  hy- 
drophilic sequences (bar in Fig.  9).  This site consists of a 
tetrapeptide Arg-Glu-Asp-Val  (REDV),  which is somewhat 
related to the RGDS sequence. To test the idea that REDV 
was the sequence in CS5 used by melanoma cells for spread- 
ing on human fibronectin, the synthetic REDV tetrapeptide 
was  tested  for  its  ability  to  promote  B16-F10 melanoma 
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Figure 10. Inhibition of B16-F10 melanoma cell 
spreading on fibronectin by REDV. (A) The per- 
centage spreading of BI6-FI0 melanoma cells on 
a substrate coated with 4 I.tg/ml fibronectin was 
determined  in  the  presence  of the  indicated 
concentrations of REDV (closed circle), RGDS 
(open circle), or RGDV (closed triangle). (B) 
Comparison of the inhibitory activity of REDV 
(closed symbols) and RGDS (open symbols) on 
B16-F10 melanoma cell spreading on fibronectin 
in the presence (triangles) or absence (circles) of 
5 I.tg/ml monoclonal antibody mAb333 (MAb). 
The coating concentration of fibronectin was 4 
~g/rra. 
spreading.  Not surprisingly, however, the tetrapeptide was 
inactive, presumably because it was too short to bind effec- 
tively to the plastic wells (data not shown). We therefore ex- 
amined  the  effect of  REDV  on  B16-F10 melanoma  cell 
spreading on fibronectin and compared its activity to that of 
RGDS and RGDV. As shown in Fig. 10 A, REDV was indeed 
inhibitory,  with  half-maximal  inhibition  occurring at  150 
Ixg/ml. However, it was also clear that the inhibitory activity 
of REDV was lower than that of either RGDS or RGDV for 
melanoma cell spreading on fibronectin (50% inhibition at 
~100 ~tg/ml; Fig.  10 A). 
From the  results  presented in  Fig.  1,  it was  clear that 
RGDS-containing peptides could interfere with the adhesion 
of B16-F10 cells, and since peptides containing both RGDS 
and  RGDV  have  been  reported  to  promote  adhesion  of 
fibroblastic cells and to inhibit their attachment to fibronectin 
(40, 41, 63, 64), these two peptides appear to be able to act 
at both adhesion sites.  The lower activity of REDV in Fig. 
10 A may therefore be due to its inability to block a potential 
contribution  from  the  RGDS-containing  site  to  B16-F10 
melanoma cell spreading. This conclusion was supported by 
the finding that REDV  was  almost completely inactive in 
blocking  fibroblastic  BHK  cell  spreading  on  fibronectin 
(data not shown). To test this possibility, the concentration 
dependence of REDV and RGDS inhibition of B16-F10 mela- 
noma cell spreading on fibronectin was examined in the pres- 
ence of 5 ~tg/ml mAb333. This antibody concentration is in 
excess of the amount required to eliminate any contribution 
from the RGDS site.  It is clear from the data in Fig.  10 B 
that in the presence of monoclonal antibody mAb333, REDV 
and RGDS actually possess approximately equal activity, as 
would be expected if REDV were the authentic adhesion site 
for B16-F10 melanoma cells and RGDS cross-reacts. The in- 
creased effectiveness of REDV in the presence of mAb333 
also demonstrates that the  RGDS  sequence in the central 
"cell-binding" domain is involved somewhat in the spreading 
of B16-FI0 melanoma on fibronectin, although its contribu- 
tion is not sufficient to allow blockage of spreading by the 
specific inhibitors t3 and mAb333 (Fig. 5). 
As a further confirmation of the identification of CS5 as 
the adhesion site for B16-F10 melanoma ceils in fibronectin, 
the profile of inhibition of spreading on CS5 by the library 
of synthetic tetra- and pentapeptides used in Fig. 1 was exam- 
ined. The relative inhibitory activities of  the peptides on CS5 
closely matched their activities on fibronectin itself; in par- 
ticular,  GRGD  and  GRGES  were  highly  inhibitory,  and 
RGDS and SDGR were both more active than GRGDS (data 
not shown). 
Discussion 
In this report, we have compared the mechanisms of interac- 
tion of B16-F10 melanoma cells and fibroblastic BHK cells 
with the adhesive glycoprotein fibronectin. Our major con- 
clusion is that the two cell lines recognize distinct adhesion 
sites within the fibronectin molecule; BHK fibroblasts use 
the previously characterized RGDS sequence located in the 
central "cell-binding" domain (40, 41, 63, 64), whereas B16- 
F10 melanoma cells recognize predominantly a novel, addi- 
tional adhesive region located in the type III connecting seg- 
ment of the molecule. At least part of this cell type-specific, 
adhesive activity is preserved in synthetic peptides contain- 
ing the active tetrapeptide REDV. 
A number of different approaches provided evidence for 
this cell type-specific recognition of different adhesion sites. 
(a) The profile of the relative idhibitory activity of a library 
of synthetic tetra- and pentapeptides was different for spread- 
ing of melanoma and fibroblastic cells on fibronectin. In par- 
ticular, GRGD (in which the COOH-terminal residue of the 
authentic GRGDS sequence was deleted) and GRGES (con- 
taining a highly conservative substitution of a single amino 
acid of identical charge within an otherwise unaltered pep- 
tide) were of comparable activity to (G)RGDS for the mela- 
noma cells, but they were completely inactive for BHK cells. 
The lack of  activity of GRGD- and GRGES-Iike peptides has 
been a consistent feature of studies with several fibroblastic 
cell lines (40, 41, 63, 64). The B16-FI0 melanoma therefore 
represents the first cell system in which GRGES has been 
found to be active in blocking adhesion to fibronectin. This 
unexpected result is discussed further below.  (b) The ability 
of melanoma and fibroblastic cells to spread on tryptic frag- 
ments of fibronectin containing the RGDS sequence was also 
different.  As  reported previously  (19),  BHK  cells  spread 
equally well on fibronectin, f13 (the RGDS-containing "cell- 
binding" domain), f7, and t9, but the B16-F10 melanoma cells 
were able to use only fibronectin and t9 (17 and 19 contain 
COOH-terminal extensions of f13, and are derived from the 
small and large subunits  of the fibronectin dimer,  respec- 
tively [19]).  t9 contains the region of the molecule that is 
thought to constitute the difference region between the two 
subunits. This 120-amino acid sequence, termed the type III 
connecting segment (IIICS) or "V" region, is alternatively 
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48,  54,  57).  (c) Molecules which inhibit cell interactions 
with  fibronectin near the RGDS recognition site (f13 and 
mAb333) completely blocked BHK fibroblast spreading on 
fibronectin but had no detectable effect on melanoma cell 
spreading. 
McCarthy et al. (32) recently reported the existence of an 
adhesion site for B16-F10 cells in a 33-kD heparin-binding 
fragment of fibronectin that may represent a site for interac- 
tion with cell surface heparan sulfate. A similar fragment has 
been reported by Woods et al. (60) to be necessary for forma- 
tion of focal contacts by cells spreading on fibronectin. In our 
studies, however, B16-F10 cells were unable to spread on the 
high affinity heparin-binding fragments present in f7 and t9 
(68), and their spreading on fibronectin was insensitive to the 
addition of  heparin, thereby demonstrating the independence 
of B16-F10 cell adhesion from the heparin-binding site.  In 
view of this result, and the reported lack of effect of RGDS 
in their adhesion assay,  the site identified in this study, and 
the  site described by McCarthy  et al.  (32)  appear to be 
distinct. 
Molecular identification of an amino acid sequence that 
could be involved in this cell type-specific spreading of B16- 
F10  melanoma  ceils  was  accomplished  by  analyzing  the 
adhesion-promoting activity of a  series of six overlapping 
synthetic peptides comprising the entire human IIICS  se- 
quence. One of these peptides, designated CS5, was able to 
mediate melanoma cell spreading  after attachment to the 
plastic substrate, while the others were inactive. For fibro- 
blastic BHK cells, all six peptides were devoid of activity. 
This result parallels the finding that BHK ceils are unable to 
use the melanoma cell adhesion site in 19, a conclusion sup- 
ported by the ability of f13 and mAb333 to completely block 
the spreading of the fibroblastic cells on fibronectin. Since 
the use of the two adhesion sites in fibronectin appears to be 
cell  type dependent,  the  intriguing  possibility  exists  that 
different cell lineages may use different adhesion signals in 
fibronectin in vivo. 
CS5 contains a sequence Arg-Glu-Asp-Val  (REDV) that is 
quite  hydrophilic  and  is  somewhat  related  to  the  RGDS 
tetrapeptide. A similar analysis of hydrophilicity previously 
pointed to the RGDS-containing region in fibronectin as a 
potentially highly exposed sequence available for interaction 
with cells (40).  Since synthetic REDV was found to be in- 
hibitory for melanoma cell spreading on both fibronectin and 
CS5, but not for BHK fibroblast spreading on fibronectin, 
this sequence appears to be an important feature of the mela- 
noma cell adhesive recognition site within the IIICS. 
As a summary of our current knowledge of the sequence 
specificities of  the adhesive signals in human fibronectin, Ta- 
ble I  compares some of the properties of the RGDS- and 
REDV-containing  sites.  Since  the  REDV  site  in  human 
fibronectin is mutated to RGDV in rat fibronectin (48), the 
activity of synthetic RGDV is also included. Several provi- 
sional conclusions are apparent. 
(a) Despite similarities in amino acid sequence, each site 
displays cell type specificity when tested for contributions 
from the other site using assays with intact fibronectin or 
large fragments. For example, autoinhibition by the f13 frag- 
ment is specific for inhibition of only the RGDS-containing 
site. 
(b) Peptide inhibitors of both sites show specificity in that 
GRDGS and unrelated peptides are inactive. The lack of ac- 
Table I. Comparisons of  the Stimulatory and Inhibitory 
Activities of  Fibronectin Fragments and Synthetic Peptides 
in Cell Adhesion Assays* 
Cell type 
BHK  BI6-FI0 
fibroblast  melanoma 
RGDS-containing site 
Promotion by f13  + 
Inhibition by mAb333  + 
Inhibition by f13  + 
Inhibition by RGDS  + 
REDV-containing site 
Promotion by CS5 
Inhibition by REDV 
Inhibition by RGDV  + 
Inhibition by GRGES, GRGD 
Other 
Inhibition by GRDGS 
Inhibition by unrelated peptides 
m 
+ 
+ 
+ 
+ 
+ 
* All inhibitory activities are for spreading on fibronectin. 
tivity after transposing residues to make GRDGS implies 
that the spacing of the Arg and Asp residues is equally criti- 
cal for both sites. 
(c) Since the estimated affinities for peptide interactions at 
both sites seem substantially lower than for the intact protein, 
additional polypeptide information appears to be needed for 
full function (see also references 1 and 4). For example, an 
as  yet unidentified,  strong,  additional  binding  site  in  the 
IIICS region may account for the 230-fold difference of ac- 
tivity compared with intact fibronectin. Such polypeptide in- 
formation also  apparently  provides  additional  specificity, 
since even though RGDS can inhibit both sites,  fragment f13 
(containing RGDS) is not active against the REDV-contain- 
ing site. 
(d) The RGDS-containing site appears more stringent than 
the  REDV-containing  site  in  its  peptide  specificity, since 
there is little cross-reacting activity of certain peptide inhibi- 
tors active at the IIICS site. One possible exception, noted 
by Schwarzbauer et al.  (48), is the RGDV sequence in rat 
fibronectin, which may mimic the RGDS site (see below). 
(e) In contrast to d  (above), the REDV-containing site is 
inhibited by several peptides from either site. The specificity 
of peptide inhibition at this site appears somewhat more re- 
laxed; some substitution at positions 2 (Gly or Glu) and 3 
(Asp or Glu) is permitted, and the Ser in position 4 may not 
be completely necessary for inhibitory activity. Perhaps the 
receptor recognizing the REDV sequence is less stringent in 
order to recognize more flexible conformations of the IIICS 
region. 
(f) The mutation of REDV to RGDV in rat may provide 
further tests  of the  sources of specificity for both  sites. 
Schwarzbauer et al.  (48) originally called attention to the 
RGDV sequence in rat, noting that it might serve as a second 
cell-binding  site  because  a  synthetic  peptide  containing 
RGDV  was  previously shown to be  similar in  activity to 
RGDS (41). It should be noted, however, that such a "second 
site" would be expected to have the same cell type specificity 
as  the prototype RGDS  site,  not the  cell type specificity 
found in our study.  In fact, rat fibronectin appears identical 
to human fibronectin in terms of adhesive function (our un- 
published  results);  in particular,  the concentration depen- 
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fibronectins is identical, the pattern of inhibition of fibronec- 
tin-mediated cell  spreading  by  short,  synthetic peptides, 
including RGDV and REDV, is similar, and f13 is unable to 
autoinhibit B16-F10 cell adhesion on either fibronectin mole- 
cule. It is thus possible that the rat RGDV sequence is func- 
tionally equivalent to REDV and used only at the IIICS site 
in conjunction with the predicted modifying polypeptide in- 
formation or third site proposed in c (above). 
The  presence  of an  adhesion  site  for  melanoma cells 
represents the first known function for the IIICS region. At 
present, five distinct fibronectin mRNA populations contain- 
ing  different spliced  products  from the  IIICS  have been 
identified in human cells (7, 28, 29, 57), two of  which contain 
the REDV sequence. The situation appears slightly less com- 
plex in the rat system, where three mRNA species have been 
identified (25,  38,  39,  47,  48,  54),  two of which contain 
RGDV.  Analysis of rat plasma fibronectin using antisera 
raised against fusion proteins containing the COOH-termi- 
na195 amino acids of the IIICS (or "V" region) revealed that 
only the large subunit(s) contained this sequence (39, 47). 
Although identical studies have not yet been performed with 
human fibronectin, the data from rat fibronectin appears to 
be consistent with the finding reported here that the mela- 
noma cell adhesion site is located only in the large subunit 
of human plasma fibronectin. 
Although our results clearly identify a novel adhesive se- 
quence, containing REDV, in a IHCS region possessing cell 
type specificity,  it should be emphasized that other specific 
adhesion sites may also exist. In particular, McCarthy et al. 
(32) have described an adhesion site in a COOH-terminal, 
heparin-binding fragment that was refractory to peptide inhi- 
bition. As noted above,  our data may also suggest the exis- 
tence of  an additional binding site in the IIICS that synergizes 
with the REDV site,  in analogy to the model we proposed 
previously for function of the prototype RGDS region (3). 
The  following speculative  argument would be  consistent 
with such a model: at least one fibrin-binding domain of hu- 
man fibronectin has been reported to contain a  carboxyl- 
terminal portion of the IIICS region when separated proteo- 
lytically from the RGDS-containing domain (cf. references 
7,  12, and 48), although the stoichiometry of this finding is 
unclear and the location of the REDV-containing region itself 
has not yet been mapped by amino acid sequencing. Since 
iS has also not been mapped by direct carboxyl-terminal se- 
quencing, it is conceivable that it lacks the REDV-containing 
region. In this case, an alternative hypothesis still consistent 
with all of our results would postulate the existence of two 
cell type-specific binding sites for melanoma cell adhesion, 
each displaying the same unusual pattern of susceptibility to 
inhibition by our peptide library. This hypothesis might also 
account for the >200-fold difference in activity between in- 
tact fibronectin (possibly containing two adhesion sites) and 
our synthetic peptide CS5 (containing only one of the sites). 
Only further extensive amino acid  sequence  and peptide 
analyses or in vitro mutagenesis studies will resolve whether 
such additional sites actually exist. 
The identification of two distinct cell adhesion sites in the 
fibronectin molecule raises the question of whether the mela- 
noma cell receptor for fibronectin is related to the previously 
identified 140-kD complex that interacts with the RGDS site 
in fibronectin (6, 16, 21, 44, 53), or whether the two adhesion 
sites interact with distinct receptors. Selective regulation of 
the quantities of two different fibronectin receptors on the 
surfaces of cells in vivo could conceivably be important bio- 
logically in modulation of adhesion during processes such as 
migration  and  embryonic development.  Developmentally 
controlled splicing that dictates the presence of the REDV 
site in the IRCS region of fibronectin would also permit the 
local regulation of cell adhesion. It may be worthwhile inves- 
tigating whether the migration and adhesion of cell types 
from the  same developmental lineage as  melanoma cells 
(e.g.,  melanocytes, peripheral neurons, other neural crest 
cell derivatives) are via the REDV site,  and hence may be 
regulated by the presence or absence of this sequence in the 
fibronectin matrix that constitutes the microenvironment of 
the cells. 
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